Table 2.

Trial outcomes categorized using the RE-AIM framework

RE-AIM domains	Trial outcomes
Reach	• Number/proportion completing Xpert testing
Effectiveness	Process outcomes • Number/proportion diagnosed with and treated for TB within 14 days • Number/proportion diagnosed with microbiologically-confirmed TB • Time to diagnosis of microbiologically-confirmed TB • Number/proportion diagnosed with rifampin resistance • Number/proportion with microbiologically-confirmed TB completing treatment Health and health economic outcomes • Number/proportion who died within 6 months • Number/proportion with microbiologically-confirmed TB who died within 6 months • Number/proportion treated for TB who died within 6 months • Incremental cost-effectiveness ratio
Adoption	• Proportion of eligible sites able and willing to initiate each component of the intervention strategy
Implementation	Fidelity • Process metrics for each intervention strategy component • Proportion tested by Xpert • Number of GeneXpert device non-operation days • Proportion of invalid, error, or indeterminate Xpert results • Proportion treated on same-day if Xpert-positive • Proportion of performance feedback report cards reviewed at staff meetings • Qualitative data from health worker focus group discussions and in-depth interviews Acceptability • Thematic output from health worker focus group discussions Patient and health system costs • Incremental cost of introducing and maintaining the intervention strategy • Incremental patient cost per diagnostic evaluation and per treatment initiated Modification of targeted barriers • Median scores for health worker knowledge, attitudes, subjective norms, and self-efficacy related to TB diagnostic evaluation guidelines • Thematic output from provider in-depth interviews • Median patient costs associated with completing TB diagnostic evaluation • Median scores for domains of patient satisfaction questionnaire